10-Q: Apellis Swings to Profit on Sobi Deal, SYFOVRE Sales Steady

Apellis Pharmaceuticals reported a significant swing to net income in Q3 2025, driven by a $275 million upfront payment from a royalty buy-down agreement with Sobi, alongside stable SYFOVRE sales and new EMPAVELI indications.

Summary

• Net income for the three months ended September 30, 2025, was $215.7 million, a substantial improvement from a net loss of $57.4 million in the same period of 2024.
• For the nine months ended September 30, 2025, net income was $81.3 million, compared to a net loss of $161.5 million in the prior year period.
• Total revenue for Q3 2025 surged to $458.6 million from $196.8 million in Q3 2024, primarily due to a $275.0 million upfront payment from the Sobi Royalty Buy-Down Agreement.
• Product revenue, net, for SYFOVRE was $150.9 million in Q3 2025, a slight decrease from $152.0 million in Q3 2024, primarily due to increased rebates partially offset by higher volume.
• Product revenue, net, for EMPAVELI increased to $26.8 million in Q3 2025 from $24.6 million in Q3 2024, driven by increased volume.
• The FDA approved EMPAVELI for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) on July 28, 2025, conditions affecting an estimated 5,000 people in the U.S.
• Research and development expenses decreased by 23% to $68.2 million in Q3 2025 and by 12% to $221.6 million for the nine months ended September 30, 2025, partly due to the discontinuation of ALS and CAD programs.
• Cash and cash equivalents stood at $479.2 million as of September 30, 2025, up from $411.3 million at December 31, 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $59.5 million, a significant improvement from $107.2 million used in operating activities in the prior year period.

Sentiment

Score: 8

Explanation: The significant swing to net income and positive operating cash flow, largely due to the Sobi royalty buy-down, coupled with a new FDA approval for EMPAVELI and pipeline advancements, indicates a strong positive financial and operational performance. While SYFOVRE revenue saw a slight dip due to rebates and EMPAVELI faced competitive pressure, the overall financial health and strategic progress are very favorable.

Positives

• Achieved a significant swing to net income of $215.7 million in Q3 2025 and $81.3 million for the nine months, compared to net losses in the prior year periods.
• Secured a $275.0 million upfront payment from Sobi through a Royalty Buy-Down Agreement, substantially boosting licensing and other revenue.
• Received FDA approval for EMPAVELI for C3G and IC-MPGN in July 2025, expanding its market to an estimated 5,000 additional U.S. patients.
• Demonstrated positive effects in the VALIANT study for C3G and IC-MPGN, including a 68% reduction in proteinuria and stabilization of kidney function.
• Improved liquidity with net cash provided by operating activities of $59.5 million for the nine months ended September 30, 2025, reversing a prior year cash outflow.
• Maintained strong cash and cash equivalents of $479.2 million, which, combined with anticipated product sales, is expected to fund operations for at least the next 12 months.
• Initiated a Phase 2 multi-dose trial for a next-generation SYFOVRE therapy (SYFOVRE + APL-3007) in GA patients in June 2025.
• Opted into a license agreement with Beam Therapeutics for a neonatal Fc receptor (FcRn) gene editing program, triggering a $3.8 million milestone payment and advancing a potential first-in-class treatment.

Negatives

• SYFOVRE net product revenue slightly decreased in Q3 2025 ($150.9 million vs $152.0 million in Q3 2024) and for the nine months ($431.7 million vs $444.0 million in 9M 2024), primarily due to increased rebates.
• EMPAVELI net product revenue for the nine months ended September 30, 2025, decreased to $67.3 million from $74.7 million in the prior year, attributed to increased competitive pressure from oral products.
• Discontinued development of systemic pegcetacoplan for Transplant-associated Thrombotic Microangiopathy (TA-TMA) following a strategic assessment.
• The option to draw an additional $100.0 million from the Credit Facility expired on September 30, 2025, as the SYFOVRE sales condition of $180.0 million trailing three-month sales was not met.
• Royalty revenue from Sobi decreased for both the three and nine months ended September 30, 2025, compared to the prior year, partly due to the royalty buy-down agreement reducing future royalty rates by 90%.

Risks

• Ongoing commercialization of EMPAVELI and SYFOVRE faces uncertainties regarding market acceptance, competition, and the rate and degree of market penetration.
• The company is subject to risks common in the biotechnology industry, including the need for additional capital, competitor innovations, successful completion of clinical trials, timely regulatory approvals, market acceptance, protection of proprietary technology, healthcare cost containment, and compliance with governmental regulations.
• Legal proceedings include a putative class action complaint and stockholder derivative lawsuits alleging misrepresentation of SYFOVRE's clinical trial design and commercial adoption risks, which could result in significant compensatory and punitive damages.
• The company's ability to fund future operations and capital expenditures depends on generating sufficient cash from product sales and potentially raising additional funds through equity offerings, debt financings, collaborations, or licensing arrangements.
• The Credit Facility contains customary covenants, including a financial covenant to maintain liquidity of at least $50.0 million if market capitalization is below $3.0 billion, and negative covenants restricting various corporate actions.
• The company is subject to restrictions on sales and licensing transactions related to its core intellectual property (SYFOVRE, EMPAVELI, and other pegcetacoplan assets) under the Sixth Street Financing Agreement.
• The Convertible Notes mature on September 15, 2026, and are now classified as a current liability, requiring potential cash or stock settlement.

Future Outlook

The company expects to continue incurring significant commercialization expenses for EMPAVELI and SYFOVRE, as well as R&D costs for ongoing and planned clinical trials. They anticipate current cash and cash equivalents, combined with future product sales, will be sufficient to fund operations and capital expenditures for at least the next 12 months. Future plans include initiating two pivotal clinical trials for EMPAVELI by year-end 2025 for primary focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF). They are also advancing a next-generation SYFOVRE therapy (APL-3007) and a gene editing treatment targeting FcRn through collaboration with Beam Therapeutics.

Management Comments

• We believe SYFOVRE has the potential to be the standard of care for patients with GA, a disease that affects an estimated 1.5 million people in the United States.
• We believe that EMPAVELI has the potential to be a best-in-class treatment for a range of indications with high unmet needs.
• We expect to initiate two pivotal clinical trials with EMPAVELI by year-end 2025, one for the treatment of primary focal segmental glomerulosclerosis, or FSGS, and one for delayed graft function, or DGF.
• Through our collaboration with Beam Therapeutics, Inc., or Beam, we have commenced preclinical studies for a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing.
• We expect that our current cash and cash equivalents of $479.2 million as of September 30, 2025, combined with cash anticipated to be generated from sales of EMPAVELI and from SYFOVRE, will be sufficient to fund our operations and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements.

Industry Context

Apellis operates in the highly competitive biopharmaceutical industry, specifically targeting complement-driven diseases. The approval of EMPAVELI for C3G and IC-MPGN expands its presence in rare nephrological conditions, a market with high unmet needs and no approved therapies. The development of a next-generation SYFOVRE therapy and a gene-editing program with Beam Therapeutics positions the company at the forefront of innovation in ophthalmology and broader complement system inhibition, aligning with industry trends towards targeted therapies and advanced modalities like gene editing. The mixed product revenue performance for SYFOVRE and EMPAVELI highlights the competitive pressures and the importance of new indications and pipeline development in maintaining market share and growth.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action complaint filed in August 2023 against the company and certain current/former executive officers, alleging violations of Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 related to SYFOVRE's clinical trials and commercial adoption risks, was dismissed without prejudice in March 2025. Plaintiffs filed an appeal in April 2025.
• Putative stockholder derivative lawsuits filed in December 2024, consolidated in January 2025, allege breach of fiduciary duty, unjust enrichment, waste, and Section 14(a) violations against the company's directors, related to SYFOVRE's clinical trials and commercial adoption risks. These cases are stayed pending the outcome of the appeal in the class action lawsuit.

Related Party Transactions

• The Royalty Buy-Down Agreement with Sobi, a collaboration partner, involved an upfront payment of $275.0 million and potential additional payments up to $25.0 million upon EMA approval for Aspaveli for C3G and IC-MPGN, in exchange for a 90% reduction in Sobi's royalty payment obligations, subject to defined caps.

Stakeholder Impact

• Shareholders: Significant increase in net income and positive operating cash flow, along with new product approvals, could positively impact shareholder value. However, ongoing legal proceedings and mixed product revenue growth for existing products present potential risks.
• Customers (Patients): FDA approval of EMPAVELI for C3G and IC-MPGN provides new treatment options for patients with high unmet needs. Continued development of SYFOVRE and other pipeline candidates aims to address further patient needs.
• Employees: Continued R&D and commercialization efforts suggest stable to growing employment opportunities, though R&D expenses decreased due to program discontinuations.
• Creditors: Improved financial performance and liquidity strengthen the company's ability to meet its debt obligations, including the Convertible Notes maturing in September 2026 and the Credit Facility.

Next Steps

• Initiate two pivotal clinical trials for EMPAVELI by year-end 2025 for primary focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF).
• Continue commercialization efforts for EMPAVELI and SYFOVRE in the U.S. and explore international expansion for SYFOVRE in select markets like Australia.
• Advance the Phase 2 multi-dose trial for SYFOVRE + APL-3007 in patients with geographic atrophy.
• Continue preclinical studies for the neonatal Fc receptor (FcRn) gene editing treatment in collaboration with Beam Therapeutics.
• Monitor and respond to ongoing legal proceedings related to SYFOVRE.

Key Dates

Recommendation

The company's significant financial turnaround, marked by a swing to net income and positive operating cash flow, is a strong indicator of improved financial health. The $275 million upfront payment from the Sobi royalty buy-down agreement provides substantial non-dilutive capital. Furthermore, the FDA approval of EMPAVELI for C3G and IC-MPGN opens up new market opportunities in rare diseases with high unmet needs, diversifying revenue streams beyond PNH and GA. While SYFOVRE's net revenue saw a slight dip due to rebates and EMPAVELI faced competitive pressure, the underlying volume growth for SYFOVRE and the strategic expansion of EMPAVELI's indications are positive. The robust pipeline, including the next-generation SYFOVRE therapy and the gene-editing collaboration with Beam Therapeutics, offers long-term growth potential. The company's liquidity position is strong, expected to fund operations for at least 12 months. Despite ongoing legal risks, the overall strategic and financial momentum suggests a favorable outlook for investors.

Keywords

Apellis Pharmaceuticals, APLS, Biopharmaceutical, Complement System, EMPAVELI, SYFOVRE, Pegcetacoplan, Geographic Atrophy, PNH, C3G, IC-MPGN, FDA Approval, Sobi, Royalty Buy-Down, Clinical Trials, Financial Results, SEC Filing, 10-Q, Biotech, Ophthalmology, Nephrology